Characteristics of pulmonary Mycobacterium avium-intracellulare complex (MAC) infection in comparison with those of tuberculosis

Respiratory Medicine

Volumn 97, Issue 6, 2003, Pages 654-659

  Watanabe, Kazuyoshi ^a   Fujimura, M ^b   Kasahara, K ^b   Yasui, M ^b   Myou, S ^b   Watanabe, A ^a   Nakao, S ^b  

^a Department of Internal Medicine   (Japan)

^b KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Mycobacterium avium complex (MAC); Mycobacterium tuberculosis; Sinusitis

Indexed keywords

CA 19-9 ANTIGEN; IMMUNOGLOBULIN A;

ADULT; AGED; ARTICLE; ATYPICAL MYCOBACTERIOSIS; CELL COUNT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HOST RESISTANCE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION RESISTANCE; LABORATORY DIAGNOSIS; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MAXILLARY SINUS; MYCOBACTERIUM INTRACELLULARE AVIUM; NEUTROPHIL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINUSITIS; SPUTUM ANALYSIS; THORAX;

EID: 0037637415     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1053/rmed.2003.1496     Document Type: Article

References (38)

1. Falkinham JO. Epidemiology of infection by nontuberculous mycobacteria. Clin Microbiol Rev 1996; 9: 177-215.
2. Wolinsky E. State of the art: nontuberculous mycobacteria and associated disease. Am Rev Respir Dis 1979; 119: 107-159.
3. Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe syndrome. Chest 1992; 101: 1605-1609.
4. Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease: incidence, presentation, and response to therapy in a community setting. Am Rev Respir Dis 1991; 143: 1381-1385.
5. Hartman TE, Swensen SJ, Williams DE. Mycobacterium avium-intracellulare complex: evaluation with CT. Radiology 1993; 187: 23-26.
6. Primack SL, Logan PM, Hartman TE, et al. Pulmonary tuberculosis and Mycobacterium avium-intracellulare: a comparison of CT findings. Radiology 1995; 194: 413-417.
7. Kubo K, Yamazaki Y, Masubuchi T, et al. Pulmonary infection with Mycobacterium avium-intracellulare leads to air trapping distal to the small airway. Am J Respir Crit Care Med 1998; 158: 979-984.
8. Yamazaki Y, Kubo K, Sekiguchi M, et al. Analysis of BAL fluid in M. avium-intracellulare infection in individuals without predisposing lung disease. Eur Respir J 1998; 11: 11227-11231.
9. Yamazaki Y, Kubo K, Takamizawa A, et al. Markers indicating deterioration of pulmonary Mycobacterium avium-intracellulare infection. Am J Respir Crit Care Med 1999; 160: 1851-1855.
10. Hashiba M., Baba S. Efficacy of long-term administration of clarithromycin in the treatment of intractable chronic sinusitis. Acta Otolaryngol 1996. 525: 73-78.
11. Suzuki H, Ikeda K, Honma R, et al. Prognostic factors of chronic rhinosinusitis under long-term low-dose macrolide therapy. ORL 1999; 62 :121-127.
12. Tomoda K, Yoneda T, Tsukaguchi K, et al. Studies on mucociliary transport in patients with pulmonary atypical mycobacteriosis. Kekkaku 1995; 70: 499-504.
13. American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 1997; 156(Suppl.): S1-S25.
14. Geckler RW, Gremillion DH, McAllister CK, et al. Microscopic and bacteriological comparision of paired sputa and pranstracheal aspiration. J Clin Microbiol 1977; 6: 396-399.
15. Hawkins JE, Wallace Jr. RJ, Brown BA. Antibacterial susceptibility tests: mycobacteria. In: Balows A. editor. Manual of clinical microbiology, 5th ed. Washington, DC: American Society for Microbiology, 1990; p 1138-1152.
16. Melen I, Lindahl L, Andresson L, et al. Chronic maxillary sinusitis. Acta Otolaryngol 1986; 101: 320-327.
17. Ishiura Y, Fujimura M, Saitou M, et al. Addictive effect of continuous low-dose ofloxacin on erythromycin therapy for sinobronchial syndrome. Respir Med 1995; 89: 677-684.
18. Homma H, Yamanaka A, Tamura M, et al. Diffuse panbronchiolitis. Chest 1983; 83: 63-69.
19. Nishimura K, Kitaichi M, Izumi T, Itoh H. Diffuse panbronchiolitis: correlation of high-resolution CT and pathologic findings. Radiology 1992; 184: 779-785.
20. Strober W, James SP. The Mucosal Immune System, in Stites, D.P. Terr, A.I. (eds.): Basic and clinical immunology, Norwalk, Appleton and Lange Medical Publications. 1991; p. 175-186.
21. Kilian J, Mastecky J, Russel MW, et al. Defense mechanisms involving Fc-dependent functions of immunoglobulin A and their subversion by bacterial immunoglobulin A proteases. Microbial Rev 1998; 52: 296-303.
22. Herlyn M, Sears HF, Steolewski Z, et al. Monoclonal antibody detection of a circulating tumor-associated antigen: I. Presence of antigen in sera of patients with colorectal, gastric, and pancreatic carcinoma. J Clin Immunol 1982; 2: 135-140.
23. Buccheri GF, Ferrigno D, Sartoris AM, et al. Tumor markers in bronhogenic carcinoma; superiority of tissue polypeptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant. Cancer 1987; 60: 42-50.
24. Yokoyama T, Ikedou Y, Kido F, et al. A study of sialylated carbohydrate antigen in patients with benign bronchopulmonary disease. Nihon Kokyuki Gakkai Zasshi 1998; 36: 851-856.
25. Roberts DD, Monsein DL, Frates RC, et al. A serum test for cystic fibrosis using monoclonal antibody 19-9. Arch Biochem Biophys 1986; 245: 292-294.
26. Mukae H, Hirota M, Kohno S, et al. Elevation of tumor-associated carbohydrate antigens in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1993; 148: 744-751.
27. Kurosu H, Washiyama M, Tada K, et al. A case of atypical mycobacteriosis accompanying elevated serum CA19-9. Nihon Kokyubu Rinshou 1993; 52: 250-254.
28. Wallace Jr. RJ, Brown BA, Griffith DE, et al. Clarithromycin regimens for pulmonary Mycobacterium avium complex: the first 50 patients. Am J Respir Crit Care Med 1996; 153:1766-1772.
29. Gilum JG, Israel DS, Polk RE. Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharamacokinet 1993; 25: 450-458.
30. Wallace Jr. RJ, Brown AB, Griffith DE, et al. Reduced serum levels of clarithromycin in patients with multidrug regimens including rifampin and rifabutin in Mycobacterium avium-intracellulare infection. Clin Infect Dis 1995; 171: 747-750.
31. Amsden GW. Macrolides versus azalides: a drug interaction update. Ann Pharmacother 1995; 29: 906-917.
32. Kudoh S, Uetake T, Hagiwara K, et al. Clinical effect of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis. Jpn J Thorac Dis 1987; 25: 632-642.
33. Yanagihara K, Tomono K, Kuroki M, et al. Intrapulmonary concentrations of inflammatory cytokines in a mouse model of chronic respiratory infection caused by Pseudomonas aeruginosa. Clin Exp Immunol 2000; 122: 67-71.
34. Yanagihara K, Tomono K, Sawai T, et al. Effect of clarithromycin on lymphocytes in chronic respiratory Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 1997; 155: 337-342.
35. Takizawa H, Desaki M, Ohtoshi T, et al. Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am J Respir Crit Care Med 1997; 156: 266-271.
36. Goswami SK, Kivity S, Marom Z. Erythromycin inhibits respiratory glycoconjugate secretion from human airways in vitro. Am Rev Respir Dis 1990; 141: 72-78.
37. Fitzgerald JE, King TE Jr, Lynch DA, et al. Diffuse panbronchiolitis in the United States. Am J Respir Crit Care Med 1996; 154: 497-503.
38. Buskin SE, Gale JL, Weiss NS, et al. Tuberculosis risk factors in adults in King Country, Washington, 1988 through 1990. Am J Public Health 1994; 84: 1750-1756.